Yasuko Fujita

Updated overall survival results from a randomized phase III trial comparing gefitinib with carboplatin–paclitaxel for chemo-naïve non-small cell lung cancer with sensitive EGFR gene mutations (NEJ002)

Akira Inoue, Kunihiko Kobayashi, Makoto Maemondo et al. · Annals of Oncology · 2012 · 549 citations

Oncology, Pathology, Cancer Treatment +6

A phase II trial of gefitinib as first-line therapy for advanced non-small cell lung cancer with epidermal growth factor receptor mutations

Hajime Asahina, K Yamazaki, Ichiro Kinoshita et al. · British Journal of Cancer · 2006 · 276 citations · Full text

Epidermal growth factor receptor expression correlates with poor prognosis in non-small cell lung cancer patients with p53 overexpression.

Yoshinobu Ohsaki, Satoshi Tanno, Yasuko Fujita et al. · Oncology Reports · 2000 · 255 citations

Effects of dapagliflozin on mortality in patients with chronic kidney disease: a pre-specified analysis from the DAPA-CKD randomized controlled trial

Hiddo J.L. Heerspink, C. David Sjöström, Niels Jongs et al. · European Heart Journal · 2021 · 118 citations · Full text

Randomized phase II study of concurrent versus sequential alternating gefitinib and chemotherapy in previously untreated non-small cell lung cancer with sensitive EGFR mutations: NEJ005/TCOG0902

Shunichi Sugawara, Satoshi Oizumi, Koichi Minato et al. · Annals of Oncology · 2015 · 110 citations

Medicine, Concurrent Versus, Pathology +7